Alessandra Dodich1, Aline Mendes2, Frédéric Assal3, Christian Chicherio4,5, Barinjaka Rakotomiaramanana6, Paulina Andryszak4,6, Cristina Festari7,8, Federica Ribaldi6,7,8, Max Scheffler9, Roger Schibli10,11, Adam J Schwarz12,13,14, Dina Zekry2, Karl-Olof Lövblad15, Marina Boccardi6,7, Paul G Unschuld16, Gabriel Gold2, Giovanni B Frisoni4,6,7, Valentina Garibotto17,18. 1. NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, 4 rue Gabrielle-Perret-Gentil, CH-1211, Geneva 14, Switzerland. alessandra.dodich@unige.ch. 2. Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland. 3. Cognitive Neurology Unit, Department of Neurology, Geneva University Hospitals, Geneva, Switzerland. 4. Memory Center - Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland. 5. Center for the Interdisciplinary Study of Gerontology and Vulnerability (CIGEV), University of Geneva, Geneva, Switzerland. 6. LANVIE - Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland. 7. LANE - Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. 8. Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 9. Radiology Division, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland. 10. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. 11. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI, Switzerland. 12. Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. 13. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA. 14. Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA. 15. Neurodiagnostic and Neurointerventional Division, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland. 16. Hospital for Psychogeriatric Medicine, Psychiatric University Hospital Zurich (PUK), Zurich, Switzerland. 17. NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, 4 rue Gabrielle-Perret-Gentil, CH-1211, Geneva 14, Switzerland. 18. Nuclear Medicine and Molecular Imaging Division, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.
Abstract
PURPOSE: The A/T/N model is a research framework proposed to investigate Alzheimer's disease (AD) pathological bases (i.e., amyloidosis A, neurofibrillary tangles T, and neurodegeneration N). The application of this system on clinical populations is still limited. The aim of the study is to evaluate the topography of T distribution by 18F-flortaucipir PET in relation to A and N and to describe the A/T/N status through imaging biomarkers in memory clinic patients. METHODS: Eighty-one patients with subjective and objective cognitive impairment were classified as A+/A- and N+/N- through amyloid PET and structural MRI. Tau deposition was compared across A/N subgroups at voxel level. T status was defined through a global cut point based on A/N subgroups and subjects were categorized following the A/T/N model. RESULTS: A+N+ and A+N- subgroups showed higher tau burden compared to A-N- group, with A+N- showing significant deposition limited to the medial and lateral temporal regions. Global cut point discriminated A+N+ and A+N- from A-N- subjects. On A/T/N classification, 23% of patients showed a negative biomarker profile, 58% fell within the Alzheimer's continuum, and 19% of the sample was characterized by non-AD pathologic change. CONCLUSION: Medial and lateral temporal regions represent a site of significant tau accumulation in A+ subjects and possibly a useful marker of early clinical changes. This is the first study in which the A/T/N model is applied using 18F-flortaucipir PET in a memory clinic population. The majority of patients showed a profile consistent with the Alzheimer's continuum, while a minor percentage showed a profile suggestive of possible other neurodegenerative diseases. These results support the applicability of the A/T/N model in clinical practice.
PURPOSE: The A/T/N model is a research framework proposed to investigate Alzheimer's disease (AD) pathological bases (i.e., amyloidosis A, neurofibrillary tangles T, and neurodegeneration N). The application of this system on clinical populations is still limited. The aim of the study is to evaluate the topography of T distribution by 18F-flortaucipir PET in relation to A and N and to describe the A/T/N status through imaging biomarkers in memory clinic patients. METHODS: Eighty-one patients with subjective and objective cognitive impairment were classified as A+/A- and N+/N- through amyloid PET and structural MRI. Tau deposition was compared across A/N subgroups at voxel level. T status was defined through a global cut point based on A/N subgroups and subjects were categorized following the A/T/N model. RESULTS: A+N+ and A+N- subgroups showed higher tau burden compared to A-N- group, with A+N- showing significant deposition limited to the medial and lateral temporal regions. Global cut point discriminated A+N+ and A+N- from A-N- subjects. On A/T/N classification, 23% of patients showed a negative biomarker profile, 58% fell within the Alzheimer's continuum, and 19% of the sample was characterized by non-AD pathologic change. CONCLUSION: Medial and lateral temporal regions represent a site of significant tau accumulation in A+ subjects and possibly a useful marker of early clinical changes. This is the first study in which the A/T/N model is applied using 18F-flortaucipir PET in a memory clinic population. The majority of patients showed a profile consistent with the Alzheimer's continuum, while a minor percentage showed a profile suggestive of possible other neurodegenerative diseases. These results support the applicability of the A/T/N model in clinical practice.
Entities:
Keywords:
18F-flortaucipir; A/T/N model; Alzheimer’s disease; PET
Authors: Paolo Bosco; Alberto Redolfi; Martina Bocchetta; Clarissa Ferrari; Anna Mega; Samantha Galluzzi; Mark Austin; Andrea Chincarini; D Louis Collins; Simon Duchesne; Bénédicte Maréchal; Alexis Roche; Francesco Sensi; Robin Wolz; Montserrat Alegret; Frederic Assal; Mircea Balasa; Christine Bastin; Anastasia Bougea; Derya Durusu Emek-Savaş; Sebastiaan Engelborghs; Timo Grimmer; Galina Grosu; Milica G Kramberger; Brian Lawlor; Gorana Mandic Stojmenovic; Mihaela Marinescu; Patrizia Mecocci; José Luis Molinuevo; Ricardo Morais; Ellis Niemantsverdriet; Flavio Nobili; Konstantinos Ntovas; Sarah O'Dwyer; George P Paraskevas; Luca Pelini; Agnese Picco; Eric Salmon; Isabel Santana; Oscar Sotolongo-Grau; Luiza Spiru; Elka Stefanova; Katarina Surlan Popovic; Magda Tsolaki; Görsev G Yener; Dina Zekry; Giovanni B Frisoni Journal: Alzheimers Dement Date: 2017-03-03 Impact factor: 21.566
Authors: Anja Soldan; Corinne Pettigrew; Anne M Fagan; Suzanne E Schindler; Abhay Moghekar; Christopher Fowler; Qiao-Xin Li; Steven J Collins; Cynthia Carlsson; Sanjay Asthana; Colin L Masters; Sterling Johnson; John C Morris; Marilyn Albert; Alden L Gross Journal: Neurology Date: 2019-03-06 Impact factor: 9.910
Authors: Sergey Shcherbinin; Adam J Schwarz; Abhinay Joshi; Michael Navitsky; Matthew Flitter; William R Shankle; Michael D Devous; Mark A Mintun Journal: J Nucl Med Date: 2016-05-05 Impact factor: 10.057
Authors: Liang Wang; Tammie L Benzinger; Yi Su; Jon Christensen; Karl Friedrichsen; Patricia Aldea; Jonathan McConathy; Nigel J Cairns; Anne M Fagan; John C Morris; Beau M Ances Journal: JAMA Neurol Date: 2016-09-01 Impact factor: 18.302
Authors: Michael Schöll; Samuel N Lockhart; Daniel R Schonhaut; James P O'Neil; Mustafa Janabi; Rik Ossenkoppele; Suzanne L Baker; Jacob W Vogel; Jamie Faria; Henry D Schwimmer; Gil D Rabinovici; William J Jagust Journal: Neuron Date: 2016-03-02 Impact factor: 17.173
Authors: P Scheltens; D Leys; F Barkhof; D Huglo; H C Weinstein; P Vermersch; M Kuiper; M Steinling; E C Wolters; J Valk Journal: J Neurol Neurosurg Psychiatry Date: 1992-10 Impact factor: 10.154
Authors: Michael Schöll; Rik Ossenkoppele; Olof Strandberg; Sebastian Palmqvist; Jonas Jögi; Tomas Ohlsson; Ruben Smith; Oskar Hansson Journal: Brain Date: 2017-09-01 Impact factor: 13.501
Authors: Hanneke F M Rhodius-Meester; Marije R Benedictus; Mike P Wattjes; Frederik Barkhof; Philip Scheltens; Majon Muller; Wiesje M van der Flier Journal: Front Aging Neurosci Date: 2017-05-09 Impact factor: 5.750
Authors: Michael J Pontecorvo; Michael D Devous; Michael Navitsky; Ming Lu; Stephen Salloway; Frederick W Schaerf; Danna Jennings; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Abhinay D Joshi; Andrew Siderowf; Mark A Mintun Journal: Brain Date: 2017-03-01 Impact factor: 13.501
Authors: Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances Journal: Sci Transl Med Date: 2016-05-11 Impact factor: 17.956
Authors: Victor L Villemagne; Frederik Barkhof; Valentina Garibotto; Susan M Landau; Agneta Nordberg; Bart N M van Berckel Journal: Radiology Date: 2021-01-19 Impact factor: 11.105
Authors: Fabio Raman; Yu-Hua Dean Fang; Sameera Grandhi; Charles F Murchison; Richard E Kennedy; John C Morris; Parinaz Massoumzadeh; Tammie Benzinger; Erik D Roberson; Jonathan McConathy Journal: J Nucl Med Date: 2021-05-28 Impact factor: 10.057
Authors: Katherine W Turk; Ana Vives-Rodriguez; Kylie A Schiloski; Anna Marin; Ryan Wang; Prabhjyot Singh; Gabor P Hajos; Rachel Powsner; Renée DeCaro; Andrew E Budson Journal: Alzheimers Dement (N Y) Date: 2022-08-17
Authors: Ana Laura Vives-Rodriguez; Kylie A Schiloski; Anna Marin; Ryan Wang; Gabor P Hajos; Rachel Powsner; Renée DeCaro; Andrew E Budson; Katherine W Turk Journal: Alzheimers Dement (N Y) Date: 2022-08-17
Authors: Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-07 Impact factor: 10.057